Shots:
- Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance OV101 into clinical
- Ovid is developing OV101 for Angelman syndrome to restore tonic inhibition addressing several core symptoms of the disease. OV101 is currently being evaluated in P-III NEPTUNE study with expected results in Q4’20
- Additionally, Ovid is exploring OV881, a microRNA approach that may reduce the expression of UBE3A-antisense and restores UBE3A expression while the company is developing OV935 (soticlestat) in collaboration with Takeda for rare developmental and epileptic encephalopathies (DEE)
Click here to read full press release/ article | Ref: Ovid Therapeutics | Image: Ovid Therapeutics
